Vision Capital Management Inc. Decreases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Vision Capital Management Inc. reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 43.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,119 shares of the biopharmaceutical company’s stock after selling 4,789 shares during the period. Vision Capital Management Inc.’s holdings in Gilead Sciences were worth $565,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC increased its position in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares in the last quarter. nVerses Capital LLC purchased a new stake in shares of Gilead Sciences in the third quarter worth about $25,000. Decker Retirement Planning Inc. purchased a new position in Gilead Sciences during the fourth quarter worth approximately $29,000. Valued Wealth Advisors LLC boosted its position in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares in the last quarter. Finally, Crews Bank & Trust purchased a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $31,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on GILD. BMO Capital Markets raised their target price on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Wells Fargo & Company raised their target price on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Royal Bank of Canada restated a “sector perform” rating and issued a $84.00 target price on shares of Gilead Sciences in a research report on Monday. Oppenheimer raised their target price on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Finally, Piper Sandler increased their price target on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $98.39.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the sale, the insider now directly owns 80,801 shares of the company’s stock, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 572,824 shares of company stock valued at $53,611,715. 0.29% of the stock is currently owned by corporate insiders.

Gilead Sciences Trading Up 1.7 %

Shares of NASDAQ GILD opened at $99.65 on Thursday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $100.51. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The stock has a fifty day simple moving average of $92.71 and a 200-day simple moving average of $86.32. The stock has a market capitalization of $124.19 billion, a PE ratio of 1,107.22, a PEG ratio of 1.37 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same period in the previous year, the firm posted $2.29 earnings per share. The company’s revenue was up 7.0% on a year-over-year basis. On average, equities analysts forecast that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.